HTG Molecular to Present a Corporate Overview at the H.C. Wainwright 20th Annual Global Investment Conference

August 30, 2018 at 4:05 PM EDT

TUCSON, Ariz., Aug. 30, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held September 4-6, 2018 at the St. Regis Hotel in New York City.

HTG Molecular Diagnostics Presentation Details
Date:   Thursday, September 6
Time:   1:45pm Eastern Time
Location:   The St. Regis New York, Louis XVI

About HTG: 
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.

Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 525-7754
Email: arr@lifesciadvisors.com 

TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
Phone: (520) 547-2827 x130
Email: tjjohnson@htgmolecular.com 

 

HTG logo

Source: HTG Molecular Diagnostics, Inc.